Boehringer Ingelheim said the laboratories would allow scientists to “achieve their goal to develop innovative therapies for ...

Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...

The solution combines three medications delivering the broadest spectrum of protection against internal and external ...

Onsite at the Boehringer Ingelheim R&D centre in Biberach, Germany, the conversation also circled around Boehringer’s One Medicine Project, originally announced in March 2022, but the central focus ...

Boehringer Ingelheim announced today that the FIBRONEERTM-IPF trial met its primary endpoint, which was the absolute change ...

The original version of this story misstated the source of Engelhorn's inheritance. She is an heir to the Boehringer Mannheim ...

Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Sept 18 (Reuters ...

Sept. 9, 2024 /PRNewswire/ -- Boehringer Ingelheim reports positive results from a Phase Ib primary analysis of Cohort 1 of the Beamion LUNG-1 trial evaluating zongertinib (BI 1810631) in pre ...

Boehringer Ingelheim is seeking regulatory approval for nerandomilast after a Phase III trial in idiopathic pulmonary fibrosis (IPF) met its primary endpoint. Boehringer confirmed the Phase III ...

Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase 3 win for a potentially first-in-class candidate and outlining plans to ...